Thomas G. Martin, MD, on Results of CARTITUDE-1 and Other Data for Cilta-Cel at ASH 2021

Video

Thomas G. Martin, MD, spoke about the previously reported results of the CARTITUDE-1 study in patients with relapsed or refractory myeloma ahead of the 2021 ASH Annual Meeting.

At the 2021 American Society of Hematology Annual Meeting, Thomas G. Martin, MD, associate director of the Myeloma Program at the University of California San Francisco, discussed the results of the CARTITUDE-1 study (NCT03548207) that investigated the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) targeting B-cell maturation antigen (BCMA) in patients with relapsed or refractory multiple myeloma.

Transcript:

The CARTITUDE-1 study was [conducted in the] United States study in which patients with relapsed or refractory myeloma were treated with ciltacabtagene autoleucel, or cilta-cel, a novel BCMA-targeted CAR T-cell therapy. Ninety-seven patients were infused with cilta-cel. [It was shown] at 1 year that the overall response rate was 97% and the stringent complete response rate was quite good at 67%. The median progression-free survival [PFS] was not reached at 12 months, the 12-month PFS rate was 77%, and the overall survival [rate] at 12 months was 89%.1

The CAR T-cell therapy is a single-agent therapy. It’s showing such an amazing response in the truly relapsed and refractory patients. These patients have had 5, 6, or 10 prior lines of therapy and really had no other options. You would expect the overall survival in that group of patients to be less than 9 months. We want to look at it in many other scenarios [such as] in early relapse with 1 to 3 prior lines of therapy. In fact, there will be a presentation at ASH using cilta-cel in [patients with] 1 to 3 prior lines of therapy.2 That will be a very interesting update in those patients.

We want to try to use [cilta-cel] in patients as part of consolidation of frontline therapy [and] using CAR T-cell therapy in lieu of or instead of autologous stem cell transplant. There are many of us who believe that CAR T-cell therapy has a more robust response rate and a deeper response than autologous transplant with less toxicity. Seeing how it performs as part of frontline therapy to see if we can even have longer remission durations in the newly diagnosed setting will be fun to watch and an important question to answer.

References

1. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8

2. Cohen YC, Cohen AD, Delforge M, et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a b-cell maturation antigen (BCMA)–directed chimeric antigen receptor (car) t-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy: updated results from CARTITUDE-2. Presented at: 63rd American Society of Hematology Annual Meeting and Exposition; December 11-14, 2021; Atlanta, GA. Abstract 3866. https://bit.ly/3GhpXUi

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content